Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07775534 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Tear Fluid for the Detection of Tumor-associated Extracellular Vesicles in Glioblastoma Patients

StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 1 year 4 months later Sep 19, 2027 → Feb 1, 2029
See other at-risk trials from City of Hope Medical Center

Record History

  1. Primary and study completion pushed from Sep 19, 2027 to Feb 1, 2029 Recruitment opened · Eligibility criteria expanded, about 14 words · Secondary endpoints: details revised at 4 of 4 entries · 1 more Show 4 more changesShow less
    • Recruitment opened
    • Eligibility criteria expanded, about 14 words
    • Secondary endpoints: details revised at 4 of 4 entries
    • Site details revised
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This clinical trial tests the impact of tear fluid in detecting tumor-associated extracellular vesicles (TEVs) in patients with glioblastoma. Brain tumors release small particles, called TEVs, that may provide information about the tumor, including how it responds to treatment. These particles can be found in cerebrospinal fluid (CSF), which is the fluid that surrounds the brain and spinal cord. Collecting CSF can be difficult and expensive, especially if samples are needed frequently to track these particles over time. Tear fluid is easier to collect than spinal fluid. If tears are found to contain similar tumor-related particles, changes in the tumor may be tracked by studying the particles found in tear fluid.
Trial Details
NCT Number NCT07775534
Lead Sponsor City of Hope Medical Center
Collaborators: National Cancer Institute (NCI)
Conditions Glioblastoma
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov